Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Amarin Stock is at Sky-High Levels Already Assumes All the Good News

By Mark R. Hake, CFA
Amarin stock is at sky high levels assuming all the good news. The FDA drug approval was anticipated and the AMRN stock price had implied it already.

Why Longer-Term Investors Should Buy Amarin Stock on Weakness

By Larry Ramer, InvestorPlace Contributor
Short sellers have targeted AMRN and the Amarin stock price is quite undervalued, making the shares quite attractive for long-term investors.

Collect on the Pharmaceutical Boom With Eli Lilly

By Ken Trester
Eli Lilly and Company (NYSE:LLY) provided optimistic guidance for 2020 today, and it looks like the stock will head higher at the open this morning.

Amarin Stock’s Big Q4 Gains May Not Last as Big Dogs are Barking

By Josh Enomoto, InvestorPlace Contributor
Thanks to the effective cardiovascular drug Vascepa, Amarin stock has enjoyed an outsized performance so far this year. However, over the horizon stands big pharmaceutical competitors that are ready to spoil the party.

3 Cancer-Fighting Drug Stocks to Buy Right Now

By Aaron Levitt, InvestorPlace Contributor
These drug stocks are among the best to buy now because each is making progress in the fight against cancer. Here's what you should know about each.

3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

By Louis Navellier, Editor, Growth Investor
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).

3 Big Pharma Stocks with Huge Future Growth Potential

By Lawrence Meyers, InvestorPlace Contributor
You don't need a dividend to have potential for big gains in big pharma stocks.

3 Soaring Pharmaceutical Stocks That Can Double in a Year

By Harriet Lefton, Writer, TipRanks
These pharmaceutical stocks have two things in common: a 'Strong Buy' analyst consensus rating and upside potential of over 100% from the current share price.

5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio

By
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must

After Johnson & Johnson (JNJ) Earnings Fail, Buy These Pharma Stocks Instead (RHHBY, SNY)

By
Shares of Johnson & Johnson slid in trading Tuesday after first-quarter earnings results disappointed. Here's where to turn in pharma today

4 Drug Stocks to Buy (CELG, EXEL, LGND, RDHL)

By
Here's a look at 4 drug stocks to buy preferred by analysts who have a deep knowledge and understanding of the industry and its companies.

The 10 Best Pharma Stocks Under President Donald Trump

By Josh Enomoto, InvestorPlace Contributor
The world was shocked by Donald Trump's surprise victory, but few equities will benefit as much as big pharma stocks.

3 Troubled Pharma Stocks That Could Rally Soon

By Josh Enomoto, InvestorPlace Contributor
Pharma stocks have been hit hard by scandals, public outcries and industry-related setbacks, but there's still hope for a recovery.

Is Pfizer Inc. Finally Safe To Buy Again? (PFE)

By Louis Navellier, Editor, Growth Investor
A first-quarter earnings and revenue beat has investors excited once again with formerly beat-down Pfizer Inc. Is now the time to buy PFE?

2 Drug Stocks To Buy For Safe Dividends And 20% Gains

By
With all the talk on the campaign trail about drug costs, it's safe to say the pharmaceutical industry is under siege. But these drug stocks are solid buys

Johnson & Johnson: How Healthy Is JNJ Stock?

By Dan Carroll, InvestorPlace Contributor
Johnson & Johnson (JNJ) stock has long been a mainstay of many investors' healthcare holdings. But is JNJ's future still bright?

Pfizer Inc. Stock: A Good Buy While the Pharma Industry Is Down (PFE)

By Marie Brodbeck, InvestorPlace Contributor
Between a planned merger with Allergan and a strong pipeline of drugs, PFE stock is a solid choice at a great price.

AZN: Why AstraZeneca’s Current Dip Is a Buying Opportunity

By Craig Adeyanju, InvestorPlace Contributor
Astrazeneca has been investing aggressively in immuno-oncology, which will make AZN stock much more attractive in the long run.

The Big Winners in Teva’s Acquisition of Allergan Generics

By Dan Burrows, InvestorPlace Feature Writer
Teva and Allergan benefit the most from the $40 billion deal, but prospects remain bright for Mylan, Perrigo and, indeed, the wider sector.
Load More